$83.81
8.83% today
Nasdaq, Apr 02, 10:11 pm CET
ISIN
US2183521028
Symbol
CORT

Corcept Therapeutics Incorporated. Stock price

$83.81
+24.74 41.88% 1M
+37.95 82.75% 6M
+33.42 66.32% YTD
+58.45 230.48% 1Y
+60.01 252.14% 3Y
+71.81 598.42% 5Y
+78.04 1,352.51% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-8.12 8.83%
ISIN
US2183521028
Symbol
CORT
Sector
Industry

Key metrics

Market capitalization $9.70b
Enterprise Value $9.32b
P/E (TTM) P/E ratio 74.55
EV/FCF (TTM) EV/FCF 47.59
EV/Sales (TTM) EV/Sales 13.81
P/S ratio (TTM) P/S ratio 14.37
P/B ratio (TTM) P/B ratio 14.22
Revenue growth (TTM) Revenue growth 39.94%
Revenue (TTM) Revenue $675.04m
EBIT (operating result TTM) EBIT $136.95m
Free Cash Flow (TTM) Free Cash Flow $195.90m
Cash position $383.33m
EPS (TTM) EPS $1.23
P/E forward 51.07
P/S forward 10.71
EV/Sales forward 10.30
Short interest 21.67%
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
100%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
675 675
40% 40%
100%
- Direct Costs 11 11
68% 68%
2%
664 664
40% 40%
98%
- Selling and Administrative Expenses 279 279
53% 53%
41%
- Research and Development Expense 247 247
34% 34%
37%
138 138
26% 26%
20%
- Depreciation and Amortization 1.34 1.34
42% 42%
0%
EBIT (Operating Income) EBIT 137 137
28% 28%
20%
Net Profit 140 140
32% 32%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Positive
Seeking Alpha
one day ago
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with end...
Positive
Seeking Alpha
one day ago
Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal, showing promise for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial demonstrated a median progression-free survival of 6.5 months and a significant overall survival gain of 4.5 months with relacorilant. Relacorilant's lack of new safety issues and potential for wide us...
Positive
Proactive Investors
2 days ago
Corcept Therapeutics (NASDAQ:CORT) shares surged more than 85% after the company announced positive results from its Phase 3 ROSELLA trial, evaluating relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer, that will support regulatory applications in the US and Europe. The trial met its primary endpoint, demonstrating a 30% reduction in the risk of disease...
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 500
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today